Shinozaki et al. introduced the potential therapeutic relevance of CLDN18 in BTCs, reporting its expression in 23–82% of BTCs, defining positivity as ≥2+ membranous staining in ≥25% of tumor cells in IHC [6]. The gene discussed is CLDN18; the disease is neoplasm.